Ivermectine Eg

Ivermectin, the active ingredient in Ivermectine Eg, is an anthelmintic (macrocyclic lactone) presented as an oral formulation for systemic use. It is employed to treat a range of parasitic infections in humans, particularly those caused by nematodes and ectoparasites.

GNH USA supplies Ivermectine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is distributed under a prescription‑only status. Our supply chain ensures consistent availability across multiple markets.

Ivermectin is an antiparasitic agent that targets a variety of helminth and ectoparasite infections.

Onchocerciasis: reduces microfilarial load and helps prevent disease progression. Strongyloidiasis: eliminates intestinal larvae and prevents disseminated infection. Scabies: eradicates Sarcoptes mites, relieving skin lesions and itching. Lymphatic filariasis: decreases adult worm burden and interrupts transmission. Other helminth infections: provides broad‑spectrum activity against several nematode species.

Ivermectin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness or light‑headedness. - Nausea, vomiting or abdominal discomfort. - Diarrhea or loose stools. - Itching or mild skin rash. - Headache. - Fatigue.

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome. - Hepatic injury or elevated liver enzymes. - Neurologic toxicity including seizures or altered mental status. - Hypotension or cardiovascular collapse. - Anaphylactic reactions.

When prescribing Ivermectine Eg, clinicians should consider several precautionary measures.

Pregnancy: safety not established; avoid unless benefit outweighs risk. Breastfeeding: unknown excretion; consider potential infant exposure. CYP3A4 inhibitors: may increase ivermectin plasma levels; monitor. Patients with CNS disorders: use with caution due to possible neurotoxicity. Renal or hepatic impairment: dose adjustment may be required. Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Ivermectin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). - P‑glycoprotein inhibitors (e.g., verapamil, quinidine). - Warfarin: may potentiate anticoagulant effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine). - Co‑administration with other antiparasitics (e.g., albendazole) may increase toxicity. - Certain antidiabetic agents (e.g., glimepiride) may have altered plasma concentrations.